- ICH GCP
- Register voor klinische proeven in de VS.
- Klinische proef NCT07324837
Enkele bolus niet-immunogeen stafylokinase bij patiënten met een acuut ischemisch cerebrovasculair accident binnen 4,5-24 uur na het begin van de symptomen (FRIDA-CT)
Een multicenter, dubbelblind, gerandomiseerd, placebo-gecontroleerd onderzoek naar de werkzaamheid en veiligheid van recombinant niet-immunogeen stafylokinase bij patiënten met een acuut ischemisch cerebrovasculair accident binnen 4,5-24 uur na het begin van de symptomen (FRIDA-CT)
Multicenter, double-blind, randomized, placebo-controlled phase III clinical trial. At the clinical sites, patients with acute ischemic stroke within 4.5-24 hours of symptom onset will be randomized to receive a single bolus injection of the recombinant non-immunogenic staphylokinase (Fortelyzin®, LLC "SuperGene", Russia) or placebo.
Studie Overzicht
Toestand
Conditie
Interventie / Behandeling
Gedetailleerde beschrijving
The current guidelines recommended intravenous thrombolysis as the first-line treatment for acute large vessel occlusion of anterior circulation stroke within 4.5 hours of stroke onset. However, a majority of patients arrive in the hospital outside the 4.5-hour time window, who could not receive intravenous thrombolysis.
In 2020, the non-immunogenic staphylokinase was registered in Russia for the acute ischemic stroke treatment within 4,5 h after the onset of symptoms. In the FRIDA randomized clinical trial the non-immunogenic staphylokinase was non-inferior to alteplase for patients with acute ischaemic stroke. Mortality, symptomatic intracranial haemorrhage, and serious adverse events did not differ significantly between groups. Non-immunogenic staphylokinase is easy to administer with a rapid single bolus of 10 mg regardless patients' bodyweight, simplifying clinical use. In 2024, the non-immunogenic staphylokinase has been included in the updated Russian clinical guidelines for the acute ischemic stroke treatment.
A rapid (10 s) single bolus of the non-immunogenic staphylokinase in patients with acute ischemic stroke may provide significant advantages over a one-hour alteplase administration in the more rapid reperfusion in the first 24 hours after thrombolysis and a greater number of good functional outcomes. It can be assumed that the non-immunogenic staphylokinase usage in patients with acute ischemic stroke outside the 4.5-hour therapeutic window will lead to the restoration of collateral blood flow in the penumbra in comparison with standard medical management.
Therefore, FRIDA-CT trial is aimed to investigate the efficacy and safety of the non-immunogenic staphylokinase within the time window of 4.5-24 hours, wake-up stroke or no witness stroke in patients who had an acute ischaemic stroke with salvageable tissue due to large vessel occlusion.
In the multicenter, double-blind, randomized, placebo-controlled phase III clinical trial patients who had an acute ischaemic stroke due to anterior circulation large vessel occlusion (internal carotid artery, middle cerebral artery M1 and M2 segments) within 4.5-24 hours from last known well (including wake-up stroke and no witness stroke) and with salvageable tissue (ischaemic core volume <70 mL, mismatch ratio ≥1.8 and mismatch volume ≥15 mL) based on CT perfusion or MRI perfusion-weighted imaging (PWI) will be included and randomised to the non-immunogenic staphylokinase, 10 mg (single bolus) regardless patient's bodyweight or placebo group. Patients who are intended for direct thrombectomy will be excluded from the trial. Follow-up period will be 90 days.
Studietype
Inschrijving (Geschat)
Fase
- Fase 3
Contacten en locaties
Studiecontact
- Naam: Nikolay A. Shamalov, MD, prof
- Telefoonnummer: +7 (499) 936-99-37
- E-mail: shamalovn@gmail.com
Studie Contact Back-up
- Naam: Natalya A. Marskaya
- Telefoonnummer: +7 (499) 936-99-37
- E-mail: marskayana@gmail.com
Studie Locaties
-
-
-
Chelyabinsk, Rusland
- Werving
- Chelyabinsk Regional Clinical Hospital No. 3
-
Contact:
- Dmitry V. Popov, PhD
- E-mail: Dmitry_popov2001@mail.ru
-
Hoofdonderzoeker:
- Dmitry V. Popov, PhD
-
Irkutsk, Rusland, 664079
- Werving
- Irkutsk Regional Clinical Hospital
-
Contact:
- Ivan V. Korobeynikov, PhD
- E-mail: Irk.ivan@gmail.com
-
Hoofdonderzoeker:
- Ivan V. Korobeynikov, PhD
-
Kazan', Rusland, 420101
- Werving
- Interregional Clinical and Diagnostic Center
-
Contact:
- Dina R. Khasanova, MD, Prof
- E-mail: dhasanova@mail.ru
-
Hoofdonderzoeker:
- Dina R. Khasanova, MD, Prof
-
Krasnodar, Rusland, 350086
- Werving
- S.V. Ochapovsky Research Institute - Regional Clinical Hospital No. 1
-
Contact:
- Ludmila V. Timchenko, MD, prof
- E-mail: tlv2908@yandex.ru
-
Hoofdonderzoeker:
- Ludmila V. Timchenko, MD, prof
-
Krasnogorsk, Rusland, 143408
- Werving
- Krasnogorsk Clinical Hospital
-
Contact:
- Svetlana V. Alexandrova
- Telefoonnummer: +7 (498) 602-03-73
- E-mail: clairalex@mail.ru
-
Hoofdonderzoeker:
- Svetlana V. Alexandrova
-
Moscow, Rusland, 108814
- Werving
- Moscow Multidisciplinary Clinical Center "Kommunarka"
-
Contact:
- Denis N. Protsenko, PhD
- Telefoonnummer: +7 (495) 744-07-03
- E-mail: ProtsenkoDN@zdrav.mos.ru
-
Hoofdonderzoeker:
- Denis N. Protsenko, PhD
-
Moscow, Rusland, 117997
- Werving
- N.I. Pirogov Russian National Research Medical University
-
Contact:
- Larisa L. Korsunskaya, MD, Prof
- E-mail: neurocrimea@mail.ru
-
Hoofdonderzoeker:
- Larisa L. Korsunskaya, MD, Prof
-
Nizhny Novgorod, Rusland, 603126
- Nog niet aan het werven
- N.A. Semashko Nizhny Novgorod Regional Clinical Hospital
-
Contact:
- Valentina N. Nesterova, PhD
- Telefoonnummer: +7 (831) 438-95-38
- E-mail: nesterova-78@mail.ru
-
Hoofdonderzoeker:
- Valentina N. Nesterova, PhD
-
Orenburg, Rusland
- Werving
- V.I. Voynov Orenburg Regional Clinical Hospital
-
Contact:
- Alexandr N. Chirkov, PhD
- E-mail: log82@mail.ru
-
Hoofdonderzoeker:
- Alexandr N. Chirkov, PhD
-
Saint Petersburg, Rusland, 193079
- Werving
- St. Petersburg Hospital for War Veterans
-
Contact:
- Maria A. Privalova, PhD
- Telefoonnummer: +7 (812) 670-94-44
- E-mail: privamariya@yandex.ru
-
Hoofdonderzoeker:
- Maria A. Privalova, PhD
-
Saint Petersburg, Rusland, 194291
- Werving
- Leningradskaya Regional Clinical Hospital
-
Contact:
- Natalya V. Zhukovskaya, MD, prof
- E-mail: nataly.lokb@mail.ru
-
Hoofdonderzoeker:
- Natalya V. Zhukovskaya, MD, prof
-
Solnechnogorsk, Rusland, 141508
- Nog niet aan het werven
- Solnechnogorsk District Hospital
-
Hoofdonderzoeker:
- Anton G. Koledinsky, MD, PhD
-
Contact:
- Anton G. Koledinsky, MD, PhD
- Telefoonnummer: +7 (496) 264-14-56
- E-mail: koledant@mail.ru
-
Tver', Rusland, 170036
- Werving
- Tver Regional Clinical Hospital
-
Contact:
- Ksenia V. Khoroshavina
- Telefoonnummer: +7 (482) 277-54-65
- E-mail: kseniarep@mail.ru
-
Hoofdonderzoeker:
- Ksenia V. Khoroshavina
-
Ulyanovsk, Rusland
- Werving
- Ulyanovsk Regional Clinical Hospital
-
Contact:
- Irina V. Greshnova, PhD
- E-mail: tonuus@mail.ru
-
Hoofdonderzoeker:
- Irina V. Greshnova, PhD
-
Volgograd, Rusland, 400138
- Werving
- City Clinical Hospital of Emergency Medical Care No. 25
-
Contact:
- Eduard A. Ponomarev, MD, prof
- E-mail: ponomarev67@mail.ru
-
Hoofdonderzoeker:
- Eduard A. Ponomarev, MD, prof
-
Yekaterinburg, Rusland, 620102
- Werving
- Sverdlovsk Regional Clinical Hospital No. 1
-
Contact:
- Andrey M. Alasheev, MD, prof
- E-mail: alasheev@live.ru
-
Hoofdonderzoeker:
- Andrey M. Alasheev, MD, prof
-
-
Ryazan Oblast
-
Ryazan, Ryazan Oblast, Rusland, 390039
- Nog niet aan het werven
- Ryazan Regional Clinical Hospital
-
Contact:
- Sergei B. Aksentyev, PhD
- E-mail: aksentievs@mail.ru
-
Hoofdonderzoeker:
- Sergei B. Aksentyev, PhD
-
-
Deelname Criteria
Geschiktheidscriteria
Leeftijden die in aanmerking komen voor studie
Accepteert gezonde vrijwilligers
Geslachten die in aanmerking komen voor studie
Beschrijving
Inclusion Criteria:
- Men and women aged 18 years and over;
- Acute ischemic stroke symptom onset between 4.5 to 24 hours prior to enrolment, including wake-up stroke and unwitnessed stroke, onset time refers to "last-seen normal time";
- Pre-stroke modified Rankin scale (mRS) score≤1;
- Internal carotid artery, middle cerebral artery M1 or M2 occlusion confirmed by CT/MRI, internal carotid artery, middle cerebral artery M1 or M2 being responsible for signs and symptoms of acute ischemic stroke;
- Neuroimaging: target mismatch profile on CT or MRI perfusion: ischemic core volume <70 mL, mismatch ratio≥1.8 and mismatch volume≥15 mL;
- Alberta Stroke Program Early CT score (ASPECTS) > 6;
- Baseline National Institutes of Health Stroke Scale (NIHSS) 6-25 (inclusive);
- The patient is not planned or cannot undergo thrombectomy or intravenous thrombolysis in accordance with the current version of the Clinical Guidelines;
- Written informed consent from patients or their legally authorized representatives.
Exclusion Criteria:
- Acute ischemic stroke within 4,5 h after symptom onset;
- Intended to proceed to endovascular treatment;
- Known hypersensitivity to the non-immunogenic staphylokinase;
- Convulsive seizures at the onset of the disease, if there is no certainty that the seizure is a clinical manifestation of acute ischemic stroke;
- Persistent blood pressure elevation (systolic ≥185 mmHg or diastolic ≥110 mmHg), and the inability to reduce systolic blood pressure below 180 mmHg or diastolic blood pressure below 105 mmHg;
- Blood glucose <2.8 or >22.2 mmol/L (after blood glucose level correction to the specified values, inclusion of the patient in the study is possible);
- Neuroimaging (CT, MRI) signs of intracranial hemorrhage, brain tumor, arteriovenous malformation, brain abscess, cerebral aneurysm;
- Subarachnoid hemorrhage;
- Major bleeding currently or within the past 6 months;
- Surgery on the brain or spinal cord in the last 2 months;
- Punctures of non-compressible arteries and veins in the last 7 days;
- Gastrointestinal or genitourinary bleeding in the last 3 weeks. Confirmed exacerbations of gastric ulcer and duodenal ulcer in the last 3 months;
- Platelet count below 100,000/mm3;
- Previous stroke or severe traumatic brain injury within 3 months;
- Unable to perform CT or MRI;
- History of hemorrhagic stroke or stroke of unspecified genesis;
- Multiple arterial occlusion (bilateral MCA occlusion, MCA occlusion accompanied with basilar occlusion);
- Concomitant use of indirect oral anticoagulants (warfarin) with INR > 1.7;
- Taking direct anticoagulants (heparin, heparinoids) in the previous 48 hours with an APTT value above normal;
- Taking new oral anticoagulants in the previous 48 hours with a thrombin time value above normal and the impossibility of administering the specific antagonist idarucizumab (for dabigatran) or the presence of anti-Xa activity (for rivaroxaban, apixaban and edoxaban).
- Severe liver disease, including liver failure, liver cirrhosis, portal hypertension (with esophageal varices), active hepatitis;
- Acute pancreatitis;
- Bacterial endocarditis, pericarditis;
- Arterial aneurysms, malformations of arteries and veins. Suspected dissecting aortic aneurysm;
- Cancer with an increased risk of bleeding;
- Major surgeries or severe injuries within the last 14 days, minor surgeries or invasive procedures within the last 10 days;
- Prolonged or traumatic cardiopulmonary resuscitation (more than 2 minutes);
- Hemorrhagic diathesis, including renal and hepatic failure;
- Data on bleeding or acute trauma (fracture) at the time of examination;
- Pregnant women, nursing mothers, or reluctant to use effective contraceptive measures during the period of trial.
Studie plan
Hoe is de studie opgezet?
Ontwerpdetails
- Primair doel: Behandeling
- Toewijzing: Gerandomiseerd
- Interventioneel model: Parallelle opdracht
- Masker: Verdrievoudigen
Wapens en interventies
Deelnemersgroep / Arm |
Interventie / Behandeling |
|---|---|
|
Placebo-vergelijker: Placebo
Placebo |
Placebo is given as a single intravenous bolus (within 5-10 seconds) immediately upon randomization |
|
Experimenteel: Non-immunogenic staphylokinase
The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight |
The non-immunogenic staphylokinase is given as a single intravenous bolus, 10 mg (within 5-10 seconds) immediately upon randomization regardless patient's bodyweight
Andere namen:
|
Wat meet het onderzoek?
Primaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Excellent functional outcome
Tijdsspanne: 90 days
|
The number of patients with excellent functional outcome defined as an mRS score 0-1 at 90 days |
90 days
|
Secundaire uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Ordinal distribution of mRS
Tijdsspanne: 90 days
|
Ordinal distribution of mRS at 90 days |
90 days
|
|
Functional independence outcome
Tijdsspanne: 90 days
|
The number of patients with functional independence defined by an mRS score 0-2 point at 90 days |
90 days
|
|
NIHSS change from baseline
Tijdsspanne: 7-14 days
|
NIHSS median change from baseline on discharge |
7-14 days
|
|
The rate of improvement on reperfusion
Tijdsspanne: 24 hours
|
The number of patients with recanalization of 2 and 3 points on the arterial occlusion scale (rAOL) 24 hours after drug administration according to CT (MRI) angiography, where 0 points - complete occlusion, 3 points - complete recanalization. |
24 hours
|
|
All-cause mortality
Tijdsspanne: 90 days
|
Rate of all-cause mortality within 90 days |
90 days
|
|
Poor functional outcome
Tijdsspanne: 90 days
|
The number of patients with poor functional outcome defined by an mRS score 5-6 point at 90 days |
90 days
|
Andere uitkomstmaten
Uitkomstmaat |
Maatregel Beschrijving |
Tijdsspanne |
|---|---|---|
|
Hemorrhagic transformation
Tijdsspanne: 24 hours
|
Rate of hemorrhagic transformation according to The Heidelberg Bleeding Classification within 24 hours |
24 hours
|
|
Symptomatic intracranial hemorrhage
Tijdsspanne: 24 hours
|
Rate of symptomatic intracranial hemorrhage (sICH) (as defined by The European Cooperative Acute Stroke Study III criteria [ECASSIII] and Safe Implementation of Thrombolysis in Stroke-Monitoring Study [SITS-MOST]) within 24 hours |
24 hours
|
|
Major bleeding
Tijdsspanne: 90 days
|
Rate of major bleeding at 90 days (as defined by the Bleeding Academic Research Consortium (BARC) scale: type 3 and type 5) |
90 days
|
|
Serious adverse events (SAEs)
Tijdsspanne: 90 days
|
Rate of serious adverse events (SAEs) within 90 days |
90 days
|
Medewerkers en onderzoekers
Sponsor
Onderzoekers
- Hoofdonderzoeker: Nikolay A. Shamalov, MD, prof, Federal Center for Brain and Neurotechnology of the Federal Medical and Biological Agency of Russia
- Studie directeur: Sergey S. Markin, MD, prof, LLC "SuperGene"
Publicaties en nuttige links
Algemene publicaties
- Gusev EI, Martynov MY, Nikonov AA, Shamalov NA, Semenov MP, Gerasimets EA, Yarovaya EB, Semenov AM, Archakov AI, Markin SS; FRIDA Study Group. Non-immunogenic recombinant staphylokinase versus alteplase for patients with acute ischaemic stroke 4.5 h after symptom onset in Russia (FRIDA): a randomised, open label, multicentre, parallel-group, non-inferiority trial. Lancet Neurol. 2021 Sep;20(9):721-728. doi: 10.1016/S1474-4422(21)00210-6.
- Shamalov NA, Martynov MY, Yarovaya EB, Chefranova ZY, Kutsenko VA, Semenov AM, Ivanov SV, Semenov MP, Markin SS, Gusev EI; FORPI Study Group. Thrombolysis With the Non-Immunogenic Staphylokinase for Acute Ischemic Stroke in the FORPI Registry: An Observational Study. Stroke. 2026 Feb;57(2):394-403. doi: 10.1161/STROKEAHA.125.051115. Epub 2025 Nov 26.
Studie record data
Bestudeer belangrijke data
Studie start (Werkelijk)
Primaire voltooiing (Geschat)
Studie voltooiing (Geschat)
Studieregistratiedata
Eerst ingediend
Eerst ingediend dat voldeed aan de QC-criteria
Eerst geplaatst (Werkelijk)
Updates van studierecords
Laatste update geplaatst (Werkelijk)
Laatste update ingediend die voldeed aan QC-criteria
Laatst geverifieerd
Meer informatie
Termen gerelateerd aan deze studie
Trefwoorden
Aanvullende relevante MeSH-voorwaarden
Andere studie-ID-nummers
- FRIDA-CT
Plan Individuele Deelnemersgegevens (IPD)
Bent u van plan om gegevens van individuele deelnemers (IPD) te delen?
Beschrijving IPD-plan
The funder of the study is committed to the responsible sharing of data from FRIDA-CT trail. Data will be provided to any qualified investigator on reasonable request. Deidentified participant data will be available after the publication of the results of the completed study on request to the corresponding author.
IPD-tijdsbestek voor delen
within 90 days after request
IPD-toegangscriteria voor delen
Proposals will be reviewed and approved by the funder and Data and Safety Monitoring Board. Once the proposal has been approved, data can be transferred through a secure online platform after the signing of a data access agreement and a confidentiality agreement.
IPD delen Ondersteunend informatietype
- LEERPROTOCOOL
- SAP
- ICF
- MVO
Informatie over medicijnen en apparaten, studiedocumenten
Bestudeert een door de Amerikaanse FDA gereguleerd geneesmiddel
Bestudeert een door de Amerikaanse FDA gereguleerd apparaatproduct
Deze informatie is zonder wijzigingen rechtstreeks van de website clinicaltrials.gov gehaald. Als u verzoeken heeft om uw onderzoeksgegevens te wijzigen, te verwijderen of bij te werken, neem dan contact op met register@clinicaltrials.gov. Zodra er een wijziging wordt doorgevoerd op clinicaltrials.gov, wordt deze ook automatisch bijgewerkt op onze website .